Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T9OC
|
|||
| Former ID |
DIB008660
|
|||
| Drug Name |
TL-118
|
|||
| Synonyms |
Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma
Click to Show/Hide
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10] | Phase 2 | [1] | |
| Company |
Tiltan pharma
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01659502) Investigator's Initiated Phase II Study for Pancreatic Cancer Patients. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.